PHASE III STUDY COMPARING RITUXIMAB-SUPPLEMENTED ABVD (R-ABVD) WITH ABVD FOLLOWED BY INVOLVED-FIELD RADIOTHERAPY (ABVD-RT) IN LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKIN'S LYMPHOMA

Trial Profile

PHASE III STUDY COMPARING RITUXIMAB-SUPPLEMENTED ABVD (R-ABVD) WITH ABVD FOLLOWED BY INVOLVED-FIELD RADIOTHERAPY (ABVD-RT) IN LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKIN'S LYMPHOMA

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Rituximab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov.
    • 09 Mar 2015 Planned primary completion date changed from 1 Sep 2012 to 1 Feb 2018 as reported by ClinicalTrials.gov.
    • 09 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top